Forte Biosciences Inc (FBRX)

$0.69

+0.03

(+4.39%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Forte Biosciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.4% return, outperforming this stock by 107.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 242.0% return, outperforming this stock by 339.6%

Performance

  • $0.65
    $0.70
    $0.69
    downward going graph

    5.8%

    Downside

    Day's Volatility :7.14%

    Upside

    1.43%

    downward going graph
  • $0.38
    $1.29
    $0.69
    downward going graph

    44.93%

    Downside

    52 Weeks Volatility :70.54%

    Upside

    46.51%

    downward going graph

Returns

PeriodForte Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
53.06%
12.8%
0.0%
6 Months
-16.38%
11.6%
0.0%
1 Year
-33.01%
15.1%
-6.4%
3 Years
-97.63%
28.9%
-22.6%

Highlights

Market Capitalization
23.6M
Book Value
$1.11
Earnings Per Share (EPS)
-1.2
Wall Street Target Price
3.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-41.72%
Return On Equity TTM
-73.23%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-31.0M
Diluted Eps TTM
-1.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-0.58
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Forte Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
00
00
Hold
1
3
3
Sell
00
3
3

Analyst Forecast

What analysts predicted

Upside of 334.78%

Current $0.69
Target $3.00

Technicals Summary

Sell

Neutral

Buy

Forte Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Forte Biosciences Inc
Forte Biosciences Inc
-1.29%
-16.38%
-33.01%
-97.63%
-99.58%
Moderna, Inc.
Moderna, Inc.
-4.6%
-14.37%
-30.73%
-33.38%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.48%
18.04%
29.62%
113.96%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
17.34%
33.21%
74.36%
242.01%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.6%
24.03%
49.67%
98.17%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Forte Biosciences Inc
Forte Biosciences Inc
NA
NA
NA
0.0
-0.73
-0.42
NA
1.11
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Forte Biosciences Inc
Forte Biosciences Inc
Buy
$23.6M
-99.58%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • Tybourne Capital Management (HK) Ltd

    9.98%
  • Perceptive Advisors LLC

    8.99%
  • Bvf Inc

    8.21%
  • Fred Alger Management, LLC

    5.06%
  • Farallon Capital Management, L.L.C.

    4.98%
  • BML Capital Management LLC

    4.85%

Corporate Announcements

  • Forte Biosciences Inc Earnings

    Forte Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he

Organization
Forte Biosciences Inc
Employees
9
CEO
Dr. Paul A. Wagner Ph.D.
Industry
Health Technology

FAQs